Skyhawk Therapeutics has received a significant financial boost in its mission to advance RNA-targeted therapies, securing an additional $2 billion from Merck KGaA. This...
Merck KGaA has raised significant concerns regarding Europe’s position in the rapidly evolving field of artificial intelligence (AI). The firm, a prominent player in...